|
The
Second European Symposium on Symptom Validity Assessment
20th - 21th May 2011 (EUR-SVA) |
||||
|
University
College London / UK
|
||||
| Commitee | |||
| Program Chair: | Dr Stuart Anderson, Hurstwood Park Neurological Centre, UK | ||
| NL | Prof
Dr Harald Merckelbach, University of Maastricht, NL Dr Ben Schmand, AMC, University of Amsterdam, NL |
||
| UK: | Dr Vicki Hacker, Brain Injury Rehabilitation Trust, Birming-ham, UK | ||
| USA: | Prof Dr Jerry Sweet, Evanston, IL, USA | ||
| Germany: | Prof
Dr Rolf Schneider, Klinikum Aschaffenburg, D Dr Thomas Merten, Krankenhaus im Friedrichshain, Berlin, D |
| Poster Commitee | Dr
Thomas Merten, D; Prof Dr Harald Merckelbach, NL Dr Ben Schmand, NL; Dr Vicki Hacker, UK |
| Organization | |||
| International
Academy of Applied Neuropsychology Semmelstr. 36/38, 97070 Würzburg, Germany Tel: +49 931 46079033, Fax: +49 931 46079034 akademie@koenigundmueller.de, www.koenigundmueller.de |
|||
| Feedback & statistics | ||
|
Are you interested
in some private
feedback? |
|
photo-retrospection
|
|
Program
|
|
Friday
20 May 2011
|
| 09:30 - 10:00 | Arrival / Registration | |||
| 10:00 - 10:10 | Welcome | Prof. Dr. Rolf Schneider and Dr. Stuart Anderson (Program Chair) | ||
|
Session
1
Symptom Validity Assessment: Introduction to Application Moderation: Kevin Greve |
| 10:10 - 10:55 | Jerry Sweet | ||
| Detecting Malingered Neurocognitive Dysfunction: Applying What We Have Learned to Individual Cases | |||
| 10:55 - 11:45 | Kyle Boone | ||
| Diagnostic
Frameworks in the Assessment of Noncredible Symptoms |
|||
| 11:45 - 12:30 | Manfred Greiffenstein | ||
| Dual
Diagnosis |
| 12:30 - 13:30 |
Lunch
+ Poster Viewing
|
|
Session
2
Symptom Validity Assessment: Methodological Issues and De-tection Strategies Moderation: Vicki Hacker |
| 13:30 - 14:15 | Kevin Greve | ||
| Malingering
Research Designs |
|||
| 14:15 - 15:00 | Kevin Bianchini | ||
| Forced
Choice Symptom Validity Tests |
| 15:00 - 15:15 |
Tea
& Coffee Break
|
|
Session
2 continued
Symptom Validity Assessment: Methodological Issues and Detection Strategies Moderation: Kevin Bianchini |
| 15:15 - 16:00 | Kyle Boone | ||
| Embedded
Symptom Validity Indicators and Recommendations for Using Multiple Symptom
Validity Indicators |
|||
| 16:00 - 16:45 | Roger Gervais | ||
| Malingering
Detection: Examples from MMPI-2-RF Applications |
|||
| 16:45 - 17:30 | Jerry Sweet | ||
| Professional
Practice Guidelines for the use and interpretation of SVTs: The Time
has Come |
| 17:30 - 18:00 |
Poster
Session
|
| 18:00 - 20:00 |
Buffet
Dinner
|
|
Saturday
21 May 2011
|
|
Session
3
Special Topics in Symptom Validity Assessment Moderation: Ben Schmand |
| 09:00 - 10:00 | Lloyd Flaro | ||
| Paediatric
Issues |
|||
| 10:00 - 10:45 | Jack Spector | ||
| Elements
of primary and secondary gain can exist in factitious disorder and malingering |
| 10:45 - 11:00 |
Tea
& Coffee Break
|
|
Session
3 continued
Special Topics in Symptom Validity Assessment Moderation: Harald Merckelbach |
| 11:00 - 11:20 | Thomas Merten | ||
| A Short
History of Resistance Against Symptom Validity Assessment |
|||
| 11:20 - 11:40 | Rolf Schneider | ||
| What
Neurologists Contribute to Identifying Malingering |
|||
| 11:40 - 12:00 | David Gill | ||
| How useful are the WAIS-III and WMS-III in symptom validity testing? | |||
| 12:00 - 12:30 | Various | ||
| Data
Blitz Session (a selection of short presentations and 5 minutes question
time) |
| 12:30 - 13:30 |
Lunch
+ Poster Viewing
|
|
Session
3 continued
Special Topics in Symptom Validity Assessment Moderation: Thomas Merten |
| 13:30 - 13:50 | Harald Merckelbach | ||
| The
Continuum Between Feigning and Somatoform Symptoms |
|||
| 13:50 - 14:40 | Kevin Bianchini | ||
| The
Financial Incentive Effect: It's Not Just Malingering |
|||
| 14:40 - 15:30 | Michael Kopelman | ||
| Problems and Issues in differentiating Neurological, Psychogenic, and Simulated Amnesia |
| 15:30 - 15:45 |
Tea
& Coffee Break
|
|
Session
3 continued
Special Topics in Symptom Validity Assessment Moderation: Manfred Greiffenstein |
| 15:45 - 16:30 | Manfred Greiffenstein | ||
| Societal
Implications of SVT Usage The closing session will comprise a brief pres-entation by Dr Greiffenstein followed by an Open Discussion in which key speakers will engage in a question and answer session with symposium delegates. |